A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

UroGen Pharma Ltd., a pioneering pharmaceutical company with a focus on innovative treatments for urothelial cancers, recently submitted an 8-K form to the Securities and Exchange Commission, ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

(RTTNews) - Bicycle Therapeutics plc (BCYC), Monday announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) ...

Ami Fadia, an analyst from Needham, maintained the Buy rating on Bicycle Therapeutics (BCYC – Research Report). The associated price target ...

First-line pembrolizumab “has consistent antitumor activity and safety” in patients with advanced urothelial carcinoma who are potentially ineligible for platinum‐based chemotherapy, researchers found ...

Biopharmaceutical company Mabwell has announced a significant milestone for its proprietary Nectin-4 targeted ADC (9MW2821).

Following a recent trial, doctors at The Christie Hospital are optimistic about the study of HMBD-001 in the treatment of ...

This pathological variant is way different from usually occurring urothelial bladder cancer. Squamous cell bladder cancer is quite aggressive in nature, rapidly progresses and spread to other ...

“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” ...